2
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
4
Glioblastoma
3
Esophageal Neoplasms
3
Recurrence
2
Esophageal Squamous Cell Carcinoma
2
Endometrial Neoplasms
2
Brain Neoplasms
2
Thyroid Neoplasms
1
Pathologic Complete Response
1
Oligodendroglioma
1
Lymphoma, Follicular
1
Lymphatic Metastasis
1
Li-Fraumeni Syndrome
1
Gliosarcoma
1
Glioma
1
Ependymoma
1
Disease
1
DWI-MRI
1
Chemotherapy Induced Cardiotoxicity in Breast Cancer Patients
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Astrocytoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Carboplatin
7
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Observation
3
Neoadjuvant Therapy
3
Epirubicin
3
Endoscopy
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Monatide (IMS 3015)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Diffusion Magnetic Resonance Imaging
×
Clear all
NCT03474341
2020-11-16
PRIDE
UMC Utrecht
Unknown
200 enrolled